EGFR and glioma: Taking into account both the preclinical and clinical experience of targeting the EGFR signaling pathway for GBM therapeutics, it can be concluded that as a monotherapy this approach is unlikely that it will work in the clinical arena, due in part to the heterogeneity of GBM and also the numerous alternative growth promoting pathways that are used by glioma cells.